Katelyn T. Byrne, Ph.D., is a newly appointed Parker Fellow at the University of Pennsylvania and an Instructor of Medicine in the Hematology/Oncology Division in the Department of Medicine at the Perelman School of Medicine. She received her B.A. in Biochemistry and Molecular Biology from Boston University and her Ph.D. in Immunology from Dartmouth College, where she trained with Dr. Mary Jo Turk, Ph.D., studying T cell memory against shared tumor-/self-antigens in melanoma.
Dr. Byrne completed her post-doctoral training at the University of Pennsylvania with Dr. Robert Vonderheide, M.D., D.Phil., investigating the mechanism of T cell activation with combined chemotherapy/CD40 stimulation in pancreatic cancer. Her interests in cancer immunotherapy include identifying the repertoire of antigens targeted by the anti-tumor T cell response and the mechanisms by which cancer-specific T cells access immune-privileged tumor sites. Dr. Byrne’s current research utilizes a genetically engineered mouse model of pancreatic cancer to investigate the dichotomy between treatment responders and non-responders, including alterations in T cell trafficking to tumors and changes in tumor-antigen presentation after therapeutic intervention.